• Histological or cytological localization is NSCLC;

• confirmed EGFR exon 19 deletion mutation(19del) or EGFR exon 21L858R mutation (L858R) or EGFR exon 20 T790M mutation (T790M)）;

• Clinical diagnosis of meningeal aggravation: clinical symptoms of intracranial hypertension (headache, dizziness, vomiting, etc.) + imaging confirmation (cerebral MRI diagnosis of meningeal aggravation) or cerebrospinal fluid cytology confirmation;

• for patients with symptoms who are considered to need temporary brain local. Treatment of cough receiving adrenal corticosteroids must be kept stable or reponse for at least 1 week before the first trial of the drug preparation;

• Newly diagnosed meningeal metastasis, including meningeal metastasis after previous brain surgery and/or local radiotherapy for solid metastatic disease;

• Patients had not received previous systemic treatment for advanced NSCLC or had meningeal metastases after treatment with one third-generation EGFR-TKI.

• Obtain informed consent signed by the patient's legal representative;

• Aged ≥18 years and ≤75 years;

• Eastern Tourism Cooperation Group (ECOG) Physical condition evaluation 0-1;

• Life expectancy ≥12 week;

• Able to follow the requirements of the study protocol and confirmation procedures, and able to accept cranial wall medications;

• contraception.